Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06624085 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A Phase 1 study of Lymphoma, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 15
- Study locations
NCT06624085: Recruiting Phase 1 study of Lymphoma, sponsored by Hoffmann-La Roche.
NCT06624085 is a Phase 1 study of Lymphoma that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 50 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (90% lower). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06624085, a Phase 1 study of Lymphoma, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Glofitamab
- DRUG Oxaliplatin
- DRUG Gemcitabine
- DRUG Tocilizumab
Study Locations (15)
California
- UC San Diego Moores Cancer Center - La Jolla
- Saddleback Memorial Medical Center - Laguna Hills
- University of California Los Angeles (UCLA) - Cancer Care - Santa Monica - Santa Monica
Texas
- Renovatio Clinical - El Paso - El Paso
- Baylor College of Medicine - Houston
- Renovatio Clinical - The Woodlands
District of Columbia
- Georgetown University - Washington D.C.
Florida
- AdventHealth Cancer Institute - Orlando
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Illinois
- University of Illinois Cancer Center - Chicago
Kansas
- Kansas City VA Medical Center - Kansas City
Maryland
- Walter Reed National Military Medical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-04-28 |
| Est. Completion | 2030-03-31 |
| Phase | Phase 1 |
What NCT06624085 shows while recruiting
NCT06624085 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Obinutuzumab is the first listed.
NCT06624085 lists 15 locations in 11 states (California, Texas, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT06624085 about?
NCT06624085 is a clinical study titled "A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma". The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
What is the current status of trial NCT06624085?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2025-04-28. Estimated completion is 2030-03-31.
What conditions does trial NCT06624085 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT06624085?
The interventions under investigation include: Obinutuzumab (DRUG), Glofitamab (DRUG), Oxaliplatin (DRUG), Gemcitabine (DRUG), Tocilizumab (DRUG).
Who is sponsoring clinical trial NCT06624085?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06624085 being conducted?
This trial has 15 study locations across California, District of Columbia, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06624085's enrollment target sits among peer trials
50 148th of 299 higher than 145 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI